SecBot SecBot
8-K ·Filed Nov 9, 2026

LRMR

Larimar Therapeutics, Inc.
BULLISH
Impact 7/10
Horizonmonths Processed7d 10h ago SEC0001193125-26-453586
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The BLA submission is a binary catalyst event. Watch for FDA acceptance for filing in early 2027 and the open label study safety update in Q1 2027. The cash runway into late Q2 2027 covers the period through potential approval and launch, but a capital raise may be needed if approval is delayed or for commercialization.

DirectionBullish
Confidencehigh
Horizonmonths

nomlabofusp

● Neutral Named in this 8-K
Impact
Phase
Filed/rolling BLA submission
Time to market
If the BLA submission is completed by end of 2026 and accepted by the FDA, a PDUFA decision on accelerated approval could come in mid-to-late 2027. A confirmatory Phase 3 trial would still be required for full approval.
Next catalyst
None dated

What to watchWatch for completion of the rolling BLA submission (remaining modules expected by end of 2026) and the FDA's subsequent acceptance for filing, which would trigger a PDUFA date assignment. The ICAR 2026 poster presentations on November 12 may provide incremental OLE data but are unlikely to be a major stock-moving event since the data is previously disclosed. The key binary catalyst remains the FDA's accelerated approval decision, likely in 2027.

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$2.69
T+0 close · Nov 9, 2026 · via day close
Latest settled
+1.49%
T+1 · $2.73 · next T+5 in 4h
Vs SPY
+0.17%
α at T+1
Latest observation
+15.52%
T+4 · FF3 residual α
  1. T+0 · Nov 10 $2.69entry
  2. T+1 · 6d ago +1.49%α +0.17% · $2.73
  3. T+4 · todayOpen
  4. T+5 · in 4h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Larimar Therapeutics completed its rolling BLA submission to the FDA seeking accelerated approval of nomlabofusp for Friedreich's ataxia, a major regulatory milestone for a clinical-stage biotech with a $245M market cap. The company also disclosed a preliminary cash balance of $128.7M as of September 30, 2026, down from $200.4M at March 31, 2026, with a projected cash runway into late Q2 2027.

Key Facts

  • Completed rolling BLA submission to FDA seeking accelerated approval of nomlabofusp for Friedreich's ataxia on November 9, 2026
  • FDA previously confirmed existing data package appears capable of supporting submission and review of a BLA seeking accelerated approval
  • FDA reaffirmed willingness to consider skin FXN as a novel surrogate endpoint
  • Preliminary cash, cash equivalents and marketable securities of $128.7M as of September 30, 2026, down from $200.4M at March 31, 2026
  • Projected cash runway into late Q2 2027
  • Potential BLA submission acceptance expected early 2027, U.S. approval mid-2027, and U.S. launch targeting Q3 2027
  • Patients currently enrolling in FORWARD-FA, the global confirmatory Phase 3 study
  • Nomlabofusp has Breakthrough Therapy, Fast Track, Rare Pediatric Disease, and Orphan Drug designations from FDA

Financial Impact

Preliminary cash balance of $128.7M as of September 30, 2026; cash runway projected into late Q2 2027

cash runway

Risk Factors

  • BLA submission does not assure acceptance for filing or accelerated approval; FDA may require additional information or studies
  • FDA may not ultimately agree that skin FXN is an acceptable surrogate endpoint for accelerated approval
  • Preliminary cash balance of $128.7M is unaudited and subject to change upon completion of quarter-end closing procedures
  • 10 cases of anaphylaxis observed in the open label study, 9 with prior nomlabofusp exposure
  • Clinical-stage biotech with no approved products or revenue

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-453586
Document: lrmr-ex99_2.htm0001193125-26-453586
Document: lrmr-ex99_1.htm0001193125-26-453586
Document: 0001193125-26-453586-index-headers.html0001193125-26-453586
Document: 0001193125-26-453586-index.html0001193125-26-453586
Document: 0001193125-26-453586.txt0001193125-26-453586
8-K Data (Synthetic)0001193125-26-453586

Track record

13 reports on LRMR

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +36.13% at T+20 after the Sep 22, 2026 report. 2 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $3.00 Now $3.00 0.00% settles Feb 12
  2. Nov 16, 2026today Press Release Bullish 7/10 Entry $3.10 Now $3.00 −3.23% settles Feb 12
  3. Nov 12, 20264d ago Insider Cluster Bullish 4/10 Entry $3.02 Now $3.00 −0.66% settles Feb 11
  4. Nov 9, 20267d ago 8-K Bullish 7/10 Viewing Entry $2.69 Now $3.00 +11.52% settles Feb 8
  5. Nov 5, 202611d ago Press Release Neutral 2/10 Entry $2.39 Now $3.00 +25.52% settles Feb 4
  6. Sep 29, 20266w ago Press Release Neutral 3/10 Entry $3.20 Now $3.00 −6.10% settles Dec 24
  7. Sep 22, 20267w ago Institutional Cluster Bearish 4/10 Entry $3.82 Now $3.00 +21.47% settles Dec 16
  8. May 14, 202626w ago 8-K Bullish 7/10 No price data
  9. May 14, 202626w ago Press Release Bullish 7/10 Entry $3.89 to $4.01 Now $3.00 −22.88% ▲ +3.08% −0.50% vs SPY
  10. Mar 19, 202634w ago Press Release Mixed 7/10 Entry $4.47 to $3.59 Now $3.00 −32.89% ▼ −19.69% −34.03% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens in 6h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026